AbbVie's (ABBV -2.67%) drug Humira is currently the best-selling medication on the planet, and it is approved to treat a wide range of diseases, including Crohn's Disease and ulcerative colitis. Recently, the company announced a partnership with a small biotech company called Galapagos to develop a JAK1 inhibitor for Crohn's Disease. In the following video, health-care analyst Max Macaluso discusses the details behind this deal and how this drug can potentially help the company maintain its lead in the autoimmune disease market in the coming years.